OXO-001 is an innovative treatment that improves the success of women’s fertility.
It acts directly on the endometrium and improves embryo implantation and post-implantation process. When launched into the market, it will be the first drug in its class and will fulfil a previously unmet medical need – the failure of embryo implantation.
Our second line of research is an innovative approach to polycystic ovary syndrome (PCOS) infertility treatment, the principal cause of infertility that affects 10% of women of child-bearing age.
